Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doravirine - Merck & Co

Drug Profile

Doravirine - Merck & Co

Alternative Names: MK-1439; MK-1439-019; Pifeltro; PIFELTRO

Latest Information Update: 04 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; National Institute of Allergy and Infectious Diseases
  • Class Antiretrovirals; Nitriles; Pyridones; Small molecules; Triazoles
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 21 Sep 2019 Launched for HIV-1 infections (Combination therapy, Treatment-experienced) in USA (PO)
  • 20 Sep 2019 Registered for HIV-1 infections (Combination therapy, Treatment-experienced) in USA (PO)
  • 01 Sep 2019 Merck and Fundacio Lluita Contra la SIDA plans the phase II DORAGEN trial in HIV 1 infections (Combination therapy, Treatment-experienced) in Spain (PO) (NCT04097925)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top